Results 31 to 40 of about 10,024 (235)
Infectious Diseases and Therapy, 2023 Introduction Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Masahiro Kimata +4 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Introduction: Randomized, controlled trials of molnupiravir in real-world use during the Omicron wave are scarce. The frequency of hospitalization and death is low, so further research is needed to confirm the virological efficacy of molnupiravir.Methods:
Yayun Liu +9 more
doaj +1 more source
Molnupiravir and risk of hospital admission or death in adults with Covid-19: Emulation of a randomized target trial using electronic health records [PDF]
, 2023 OBJECTIVE: To emulate a randomized target trial to estimate the association between the antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 infection in the community during the omicron predominant era who were at high ...
Al-Aly, Ziyad, Bowe, Benjamin, Xie, Yan
core +2 more sources
Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
International Journal of Antimicrobial Agents, 2023 Background Molnupiravir is an essential oral antiviral agent against coronavirus disease 2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients undergoing haemodialysis (HD).
Yi-Chin Chang +9 more
semanticscholar +1 more source
Molnupiravir and risk of post-acute sequelae of covid-19: Cohort study [PDF]
, 2023 OBJECTIVE: To examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes. DESIGN: Cohort study.
Al-Aly, Ziyad, Choi, Taeyoung, Xie, Yan
core +2 more sources
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
Viruses, 2023 Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in animal models of COVID-19, prompting clinical trials, in which initial results indicated a significant effect against the disease.
Henrik Berg Rasmussen, Peter Riis Hansen
doaj +1 more source
EBioMedicine, 2023 Summary: Background: Molnupiravir is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC) and is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang +6 more
doaj +1 more source
New analytical method development and validation for estimation of molnupiravir in bulk and tablet dosage form by RP-HPLC method [PDF]
Cellular, Molecular and Biomedical Reports, 2023 A new simple, selective, rapid, precise reversed-phase high-performance liquid chromatography method has been developed and validated for the estimation of Molnupiravir in bulk and its pharmaceutical dosage form.
Gandu Sravanthi +2 more
doaj +1 more source
Molnupiravir for treating COVID-19 [PDF]
Cochrane Database of Systematic Reviews, 2022 Objectives\ud This is a protocol for a Cochrane Review (intervention). The objectives are as follows:\ud \ud To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.
Ochodo, Eleanor +7 more
openaire +1 more source
Communications Medicine, 2023 Background The antiviral drug molnupiravir is an orally bioavailable prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC), which is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang +6 more
doaj +1 more source